Категории

The effect of estrogen on the brain

Опубликовано: 27 Июль 2017
на канале: VJDementia
74k
688

Смотрите видео The effect of estrogen on the brain онлайн без регистрации, длительностью 03 минут 48 секунд в хорошем hd качестве. Это видео добавил пользователь VJDementia 27 Июль 2017, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 74 тысяч раз и оно понравилось 68 людям.

play_arrow
3,09
24

Jean-Claude Van Damme - Facial Expressions in movies. A great actor!

Jean-Claude Van Damme - Facial Expressions in movies. A great actor!
play_arrow
99
1

mitski - first love/late spring //speed up//

mitski - first love/late spring //speed up//
play_arrow
511,41
5.8 тыс

Why are These Fortnite Maps so Popular?

Why are These Fortnite Maps so Popular?
play_arrow

July 10, 2024

July 10, 2024
play_arrow
40
lik

Live Immortal Rank Push | Mobile Legends 5vs5

Live Immortal Rank Push | Mobile Legends 5vs5
play_arrow
19,69
8

Кто перепел Билли Айлиш? Учим английский по шоу Голос. | The Voice: лучшее.

Кто перепел Билли Айлиш? Учим английский по шоу Голос. | The Voice: лучшее.
play_arrow
2,57
2

Never Have I Ever... - General Questions Edition

Never Have I Ever... - General Questions Edition
play_arrow
4

WOT | ФАРМ НА 100 🍋 СЕРЕБРА (ЧАСТЬ 2) | World of Tanks rascal23 СТРИМ

WOT | ФАРМ НА 100 🍋 СЕРЕБРА (ЧАСТЬ 2) | World of Tanks rascal23 СТРИМ
Похожие видео
play_arrow
Plasma p-tau217: a cost-effective and practical surrogate biomarker for clinical trials

Plasma p-tau217: a cost-effective and practical surrogate biomarker for clinical trials
play_arrow
Objective monitoring of activities of daily living: IADLSys Smart-Home approach

Objective monitoring of activities of daily living: IADLSys Smart-Home approach
play_arrow
Amyloid reduction as a surrogate endpoint in Alzheimer’s disease trials: insights from DIAN-TU

Amyloid reduction as a surrogate endpoint in Alzheimer’s disease trials: insights from DIAN-TU
play_arrow
Unraveling the oligomer hypothesis in Alzheimer’s disease

Unraveling the oligomer hypothesis in Alzheimer’s disease
play_arrow
SEMA4D as a therapeutic target: insights from SIGNAL-HD and implications for Alzheimer's disease

SEMA4D as a therapeutic target: insights from SIGNAL-HD and implications for Alzheimer's disease
play_arrow
SIGNAL-AD study of pepinemab in Alzheimer’s disease

SIGNAL-AD study of pepinemab in Alzheimer’s disease
play_arrow
ACU193 in Alzheimer's disease: insights from the INTERCEPT AD study

ACU193 in Alzheimer's disease: insights from the INTERCEPT AD study
play_arrow
Speech biomarkers for cognitive decline detection

Speech biomarkers for cognitive decline detection
play_arrow
Plasma biomarkers for population-based Alzheimer’s disease screening

Plasma biomarkers for population-based Alzheimer’s disease screening
play_arrow
Amyloid-PET positivity cut-offs: insights from INTERCEPT-AD

Amyloid-PET positivity cut-offs: insights from INTERCEPT-AD
play_arrow
Measuring treatment effect in Alzheimer’s disease clinical trials: the ‘time saved’ approach

Measuring treatment effect in Alzheimer’s disease clinical trials: the ‘time saved’ approach
play_arrow
Targeting brain metabolism in Alzheimer’s disease: results from the PIONEER trial

Targeting brain metabolism in Alzheimer’s disease: results from the PIONEER trial